

Ad Hoc Release

MediGene AG Decides to Raise Cash by Means of Share Capital Increase under Exclusion of Subscription Rights

Martinsried/Munich, February 14, 2007. Today the Executive Board of the biotech company MediGene AG (Frankfurt, Prime Standard: MDG) decided, with the Supervisory Board's consent, to increase the company's share capital from EUR 28,780,799.00 by EUR 2,062,040.00 to EUR 30,842,839.00, by cash contribution and utilizing the approved capital. The capital increase is carried out under exclusion of subscription rights. As Sole Lead Manager DZ BANK will offer the new shares with institutional investors in Germany and Europe at a price close to market by means of an accelerated bookbuilding process.

The proceeds from the capital increase are intended for the set-up of a sales force in the field of dermatology, and for further financing the current research and development projects.

No offering:

This announcement does not constitute, or form part of an offer or solicitation of an offer to purchase or subscribe for securities in the United States or any other jurisdiction. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States, except pursuant to an available exemption from registration. No public offering of securities is being made in the United States.

- Ende -

Contact MediGene AG

Email: investor@medigene.com

Fax: ++49 - 89 - 85 65 - 2920

Julia Hofmann / Dr. Georg Dönges, Public Relations, Tel.: ++49 - 89 - 85 65 - 3317

Dr. Michael Nettersheim, Investor Relations, Tel.: ++49 - 89 - 85 65 - 2946